$GILD Gilead Q1 results 'outstanding,' says Wells Fargo After Gilead reported stronger than expected Q1 results, Wells Fargo thinks that the company's Sovaldi sales likely exceeded most Street estimates. The firm thinks the strong Sovaldi launch bodes well for the drug's long-term outlook. It keeps an $87-$91 price target and Outperform rating on the stock
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.